Keeping Track: Ticovac Is Latest Win For Pfizer’s Vaccine Business; Doors Open For BMS And GSK PD-1 Inhibitors

 
• By Bridget Silverman
Keeping Track Feature image
GlaxoSmithKline’s Jemperli joined the small group of products with tissue-agnostic cancer therapy indications in the US.

More from Approvals

More from Product Reviews